Insider · CIK 0002087469
Kent Edward Kester
Files at TTRX (Turn Therapeutics Inc.). First filing -, latest -.
In brief
Kent Edward Kester files SEC Form 4 as director at TTRX (Turn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Kent Edward Kester has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | TTRX Turn Therapeutics Inc. | AGrant or award Stock option (right to buy)derivative | +83,334 | $0.00 | $0 | 83,334 | Jun 8, 2026 |
| Oct 8, 2025 | TTRX Turn Therapeutics Inc. | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | Oct 10, 2025 |
Questions about Kent Edward Kester
Answered from the filings on this page, as of the latest one.
Is Kent Edward Kester buying or selling?
Kent Edward Kester has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Kent Edward Kester's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kent Edward Kester has 0.
Where does Kent Edward Kester file Form 4?
Kent Edward Kester has filed Form 4 at TTRX (Turn Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.